- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
For Uninfected Partner, Antiretroviral Drugs May Shield Against HIV
TUESDAY, Sept. 10Antiretroviral drugs can provide a high level of protection against HIV for uninfected people in heterosexual couples in which the other partner has HIV, according to a new study.
The study included more than 1,100 HIV-uninfected people in Uganda who had a partner with HIV, the virus that causes AIDS. The participants were given antiretroviral drugs and received counseling support throughout the study to help them adhere to their drug regimen.
The drug adherence rate was 97 percent to 99 percent in the study, which was published Sept. 10 in the journal PLoS Medicine.
After an average follow-up period of 11 months, just 14 of the participants became infected with HIV, according to a journal news release.
The findings provide further proof that strict adherence to what is called antiretroviral pre-exposure prophylaxis offers high levels of protection to uninfected people, said Jessica Haberer, of Harvard Medical School, and colleagues.
The researchers said several previous studies in various groups (such as men who have sex with men, or women at high risk for HIV) have shown that taking antiretroviral drugs provided uninfected people with varying levels of protection against HIV. One possible explanation for the range of findings is different levels of adherence to the antiretroviral drugs, the researchers said.
“Proper support and assessment of adherence will be critical for determining efficacy of [pre-exposure prophylaxis] outside of clinical trials,” the study authors wrote. “This data will be important for guiding ethical decisions about resource allocation for both prevention and treatment of HIV.”
The Bill & Melinda Gates Foundation funded the study.
More information
The U.S. Centers for Disease Control and Prevention has more about pre-exposure prophylaxis.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.